📰 Lobe Sciences Ltd News
Page 2 - Lobe Sciences Ltd News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Lobe Sciences Ltd. Real-time updates on events, politics, business and more.
September 18, 2023
VANCOUVER, British Columbia — Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company”), a North American Biopharmaceutical Company committed to…
September 18, 2023
Lobe Sciences Ltd. that Mathew Lee will join the organization as Chief Financial Officer, effective September 18, 2023. Mathew has over 15 years of experience as a finance executive. Mathew currently...
September 15, 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced that on August 30, 2023 it signed an amendment to...
July 29, 2023
/PRNewswire/ -- The "Transmucosal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key...
June 29, 2023
Lobe Sciences Ltd. LOBEF, a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has…
June 28, 2023
Lobe Sciences Ltd. (OTCQB: LOBEF), a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical study on proprietary psilocin analog L-130. 
June 27, 2023
As part of the renewed interest in the potential health applications of psychedelics in recent years, companies ranging from biotechnology startups to...
June 13, 2023
Psychedelic stocks are trading so low right now that there is no better time to invest, according to one venture capital firm. Investors have been given...
June 7, 2023
Phillips also named President of Altemia & Co., a Lobe Sciences Company ... | June 7, 2023